ArticleScientific reports2024
The effects of hesperidin on valproic acid-induced reduction in hippocampal neurogenesis through the antioxidant and apoptotic pathways in adult rats.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A Combination of Artemisinin, N-acetylcysteine, Resveratrol, and Hesperidin Ameliorates Hippocampal Damage and Pathological Features in an Experimental Model of Alzheimer's Disease.Neurochemical research · 2026Article
- Valproic Acid Induces Post-Translational Redox Modifications in Mouse Embryos That Are Prevented via Prior Nrf2 Activation.Journal of developmental biology · 2026Article
- Integration of Metabolic Pathways and Micronutrient Signals Influences Neurodevelopment by Modulating Neural Stem Cell Dynamics.Molecular neurobiology · 2026Review
- Article
- Indole-3-acetic acid and chenodeoxycholic acid attenuate TLR4/NF-κB signaling and endoplasmic reticulum stress in valproic acid-induced neurotoxicity.Frontiers in pharmacology · 2025Article
- Recent insights into the biological functions of hesperidin.EXCLI journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Treatment with valproic acid (VPA) can induce oxidative stress, leading to neuronal degeneration. Hesperidin (HSD) has an antioxidant function that can mitigate oxidative stress, thereby promoting hippocampal neurogenesis. Because brain function and memory are reliant on hippocampal neurogenesis, this work is planned to elucidate the effects of HSD on the VPA-induced alterations in hippocampal neurogenesis and apoptosis via oxidative damage. Twenty-four male Sprague-Dawley rats were grouped into the vehicle, VPA, HSD, and VPA + HSD groups. After administration, the hippocampi and prefrontal cortex were harvested for p21 staining, assessment of MDA, CAT, SOD, and GPx, and Western blotting analysis of Nrf2, Bax, caspase3, and Bcl-2 proteins. The results exhibited a significantly elevated level of p21-positive cells in VPA-treated rats, indicating cell cycle arrest in hippocampal neurogenesis. Additionally, our findings demonstrated a notable rise in oxidative stress, a decrease in antioxidant enzyme activity and the transcription factor Nrf2 in VPA-treated rats. Furthermore, VPA induced apoptotic activities, as substantiated by the upregulation of Bax and caspase3, and the downregulation of Bcl-2. These findings demonstrate that HSD can reduce oxidative stress levels, thereby mitigating the arrest of the cell cycle and apoptotic activity induced by VPA treatment in both the hippocampus and prefrontal cortex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.